Disseminating clinical trial results in critical care

被引:25
作者
Kahn, Jeremy M. [1 ,2 ,3 ]
机构
[1] Univ Penn, Sch Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA
[2] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
关键词
clinical trials; diffusion of innovation; information dissemination; registries; critical care; intensive care; sepsis; drotrecogin alfa (activated); mechanical ventilation; acute lung injury; LUNG-PROTECTIVE VENTILATION; GOAL-DIRECTED THERAPY; SEVERE SEPSIS; SEPTIC SHOCK; QUALITY IMPROVEMENT; PARTICIPATORY RESEARCH; MECHANICAL VENTILATION; UNITED-STATES; COMMUNITY; GUIDELINES;
D O I
10.1097/CCM.0b013e3181920fa3
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Efficient translation of clinical evidence into clinical practice is among the greatest challenges to evidence-based medicine. The field of knowledge transfer seeks to understand the barriers to evidence uptake and develop new methods to effectively disseminate clinical trial results. Traditionally, barriers to evidence-based practice are categorized into those of knowledge, attitudes, and behavior. Efforts to improve translation of evidence into practice should uncover and address each of these barriers and be customized to the specific intervention. To help aid knowledge transfer, interventions in clinical trials should be as simple as possible and answer questions important to actual caregivers. Potentially innovative methods for improving knowledge transfer include expanding community research networks, clinical registries to monitor evidence uptake, and community-based participatory research. It is essential that investigators conducting clinical trials prioritize knowledge transfer to ensure that new therapies in critical care are actually reaching the critically ill. (Crit Care Med 2009; 37[Suppl.]:S147-S153)
引用
收藏
页码:S147 / S153
页数:7
相关论文
共 79 条
[1]   Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death [J].
Abraham, E ;
Laterre, P ;
Garg, R ;
Levy, H ;
Talwar, D ;
Trzaskoma, BL ;
Francois, B ;
Guy, JS ;
Bruckmann, M ;
Rea-Neto, A ;
Rossaint, R ;
Perrotin, D ;
Sablotzki, A ;
Arkins, N ;
Utterback, BG ;
Macias, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) :1332-1341
[2]  
*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801
[3]  
[Anonymous], 2003, Epidemiologic methods: studying the occurrence of illness
[4]  
[Anonymous], PROTOCOLIZED CARE EA
[5]   The effect of publicly reporting hospital performance on market share and risk-adjusted mortality at high-mortality hospitals [J].
Baker, DW ;
Einstadter, D ;
Thomas, C ;
Husak, S ;
Gordon, NH ;
Cebul, RD .
MEDICAL CARE, 2003, 41 (06) :729-740
[6]   Prioritizing the organization and management of intensive care services in the United States: The PrOMIS Conference [J].
Barnato, Amber E. ;
Kahn, Jeremy M. ;
Rubenfeld, Gordon D. ;
McCauley, Kathleen ;
Fontaine, Dorrie ;
Frassica, Joseph J. ;
Hubmayr, Rolf ;
Jacobi, Judith ;
Brower, Roy G. ;
Chalfin, Donald ;
Sibbald, William ;
Asch, David A. ;
Kelley, Mark ;
Angus, Derek C. .
CRITICAL CARE MEDICINE, 2007, 35 (04) :1003-1011
[7]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[8]  
Bero LA, 1998, BMJ-BRIT MED J, V317, P465
[9]   Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey [J].
Bertolini, Guido ;
Rossi, Carlotta ;
Anghileri, Abramo ;
Livigni, Sergio ;
Addis, Antonio ;
Poole, Daniele .
INTENSIVE CARE MEDICINE, 2007, 33 (03) :426-434
[10]   Disseminating innovations in health care [J].
Berwick, DM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (15) :1969-1975